When was Barinthus Biotherapeutics founded?

Barinthus Biotherapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Barinthus Biotherapeutics located?

Barinthus Biotherapeutics is headquartered in Germantown, United States. It is registered at UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE,HARWELL,DIDCOT,UNITED KINGDOM,OX11 0DF.

Who is the current CEO of Barinthus Biotherapeutics?

Bill Enright of Barinthus Biotherapeutics.

Which legal entities is Barinthus Biotherapeutics associated with?

Barinthus Biotherapeutics is associated with VACCITECH (UK) LIMITED and 2 others.

How many employees does Barinthus Biotherapeutics have?

As of Mar 31, 2026, the latest employee count at Barinthus Biotherapeutics is 36.

Is Barinthus Biotherapeutics a funded company?

Barinthus Biotherapeutics is a funded company, having raised a total of $210M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 12, 2016.

When was the latest funding round of Barinthus Biotherapeutics?

Barinthus Biotherapeutics' latest funding was a $***** Post IPO round on Dec 25, 2023, with participation from 1 investor.

What is the annual revenue of Barinthus Biotherapeutics?

Annual revenue of Barinthus Biotherapeutics is $15M as on Dec 31, 2024.

Where does Barinthus Biotherapeutics rank among its competitors?

Barinthus Biotherapeutics ranks 53rd amongst 2576 active competitors, of which 891 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Barinthus Biotherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Barinthus Biotherapeutics is a public company based in Germantown (United States), founded in 2016 by Adrian V S Hill and Sarah Gilbert. It operates as a Developer of T-cell immunotherapeutics to treat multiple diseases. Barinthus Biotherapeutics has raised $210M in funding from investors like Oxford Science Enterprises, Sequoia Capital and Google Ventures. The company has 2576 active competitors, including 891 funded and 648 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology.

Company Details

Developer of T-cell immunotherapeutics to treat multiple diseases. The company has proprietary platform technologies ChAdOx, MVA, SNAP-TI, and SNAP-CI to develop pipeline of product candidates across a diverse range of therapeutic areas including chronic infectious diseases, autoimmunity, and cancer.

Website: barinthusbio.com
Social
Email ID: *****@barinthusbio.com
Phone Number: +1 **********
Registered Address: UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE,HARWELL,DIDCOT,UNITED KINGDOM,OX11 0DF

Key Metrics

Founded Year

2016

Location

Germantown, United States

Stage

Public

Total Funding

$210M in 4 rounds

Latest Funding Round

Post IPO, Dec 25, 2023, $*****

Investors

Oxford Science Enterprises & 12 more

Ranked

53^rd among 2576 active competitors

Annual Revenue

$15M as on Dec 31, 2024

Employee Count

36 as on Mar 31, 2026

Similar Companies

BACTOLIFE & 240 more

Exit Details

Public

View Barinthus Biotherapeutics' full profile

Barinthus Biotherapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VACCITECH PLC CIN: 1828185 , United States, Active		$15M (As on Dec 31, 2024)	-	-
VACCITECH (UK) LIMITED CIN: 9973585 , United Kingdom, Active	Jan 26, 2016	-	-
VACCITECH LIMITED CIN: 09973585 , United Kingdom, Active	Jan 26, 2016	$7.05M (As on Dec 31, 2019)	72 (As on Dec 31, 2021)

Barinthus Biotherapeutics got listed on Apr 30, 2021.

Click here to take a look at Barinthus Biotherapeutics's IPO in detail

Barinthus Biotherapeutics has raised a total funding of $210M over 4 rounds. Its first funding round was on May 12, 2016. Its latest funding round was a Post IPO round on Dec 25, 2023 for $*****. 1 investor participated in its latest round. Barinthus Biotherapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Barinthus Biotherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 25, 2023	8857096	Post IPO	7752450	2196152	4561363	4528251
Mar 17, 2021	9292900	Series B	6815743	7380861	3064030	Future Planet Capital & 3 more
Jan 14, 2018	1644290	Series A	6621022	7516307	Sequoia Capital & 2 more	Neptune Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Barinthus Biotherapeutics's funding rounds and investors

The founders of Barinthus Biotherapeutics are Adrian V S Hill and Sarah Gilbert. Bill Enright is the CEO of Barinthus Biotherapeutics.

Here are the details of Barinthus Biotherapeutics' key team members:

Adrian V S Hill: Co-Founder of Barinthus Biotherapeutics.
Sarah Gilbert: Co-Founder of Barinthus Biotherapeutics.
Bill Enright: CEO of Barinthus Biotherapeutics.
Contact Info: 1 email address

View details of Barinthus Biotherapeutics's Founder profiles and Board Members

Barinthus Biotherapeutics' employee count trend

Barinthus Biotherapeutics has 36 employees as of Mar 26. Here is Barinthus Biotherapeutics's employee count trend over the years:

Employee count trend for Barinthus Biotherapeutics

Uncover Barinthus Biotherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Barinthus Biotherapeutics include Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology. Here is the list of Top 10 competitors of Barinthus Biotherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, BVF Partners & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
9th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
53rd	Barinthus Biotherapeutics 2016, Germantown (United States), Public	Developer of T-cell immunotherapeutics to treat multiple diseases	$210M	HTIF, Gilead & 11 others	66/100